Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice.
Cortellini A, Tucci M, Adamo V, Stucci LS, Russo A, Tanda ET, Spagnolo F, Rastelli F, Bisonni R, Santini D, Russano M, Anesi C, Giusti R, Filetti M, Marchetti P, Botticelli A, Gelibter A, Occhipinti MA, Marconcini R, Vitale MG, Nicolardi L, Chiari R, Bareggi C, Nigro O, Tuzi A, De Tursi M, Petragnani N, Pala L, Bracarda S, Macrini S, Inno A, Zoratto F, Veltri E, Di Cocco B, Mallardo D, Vitale MG, Pinato DJ, Porzio G, Ficorella C, Ascierto PA. Cortellini A, et al. Among authors: petragnani n. J Immunother Cancer. 2020 Nov;8(2):e001361. doi: 10.1136/jitc-2020-001361. J Immunother Cancer. 2020. PMID: 33154150 Free PMC article.
A multicentre study with real-world data of the use of palbociclib in the treatment of breast cancer: Treatment duration correlates with dose reductions.
Musicco F, Lasala R, Santoleri F, Costantini A, Abrate P, Carretta MT, Proli EM, Romagnoli A, Petragnani N, Vita F, Zeuli M, Vici P, Sansone M, Pasquantonio M, La Malfa A, Fulgenzio C. Musicco F, et al. Among authors: petragnani n. J Oncol Pharm Pract. 2023 Dec;29(8):1806-1815. doi: 10.1177/10781552221117135. Epub 2022 Jul 29. J Oncol Pharm Pract. 2023. PMID: 35903919
Discovery of the First-in-Class GSK-3β/HDAC Dual Inhibitor as Disease-Modifying Agent To Combat Alzheimer's Disease.
De Simone A, La Pietra V, Betari N, Petragnani N, Conte M, Daniele S, Pietrobono D, Martini C, Petralla S, Casadei R, Davani L, Frabetti F, Russomanno P, Novellino E, Montanari S, Tumiatti V, Ballerini P, Sarno F, Nebbioso A, Altucci L, Monti B, Andrisano V, Milelli A. De Simone A, et al. Among authors: petragnani n. ACS Med Chem Lett. 2019 Feb 4;10(4):469-474. doi: 10.1021/acsmedchemlett.8b00507. eCollection 2019 Apr 11. ACS Med Chem Lett. 2019. PMID: 30996781 Free PMC article.
Correction to "Discovery of the First-in-Class GSK-3β/HDAC Dual Inhibitor as Disease-Modifying Agent To Combat Alzheimer's Disease".
De Simone A, La Pietra V, Betari N, Petragnani N, Conte M, Daniele S, Pietrobono D, Martini C, Petralla S, Casadei R, Davani L, Frabetti F, Russomanno P, Novellino E, Montanari S, Tumiatti V, Ballerini P, Sarno F, Nebbioso A, Altucci L, Monti B, Andrisano V, Milelli A. De Simone A, et al. Among authors: petragnani n. ACS Med Chem Lett. 2019 Aug 6;10(9):1357. doi: 10.1021/acsmedchemlett.9b00316. eCollection 2019 Sep 12. ACS Med Chem Lett. 2019. PMID: 31531210 Free PMC article.
16 results